Open Access Open Access  Restricted Access Subscription Access

METHOTREXATE: A PHARMACOLOGICAL REVIEW

AKHILA T BABU, HANNAH ALIYAMMA ALEX

Abstract


Methotrexate is a member of pteridine family, a monocarboxylic acid amide and a dicarboxylic acid. It  act as a dihydrofolate reductase asset, a DNA inhibitor, an abortifacient, a dermatologic medicine, and an immunosuppressive agent. MTX serves as the primary DMARD for RA, psoriasis, and other conditions due to its anti-inflammatory and immunomodulatory properties. This review outlines MTX's emerging pharmacological effects in various diseases, including rheumatism, cancer, myasthenia gravis, Alzheimer’s disease, and skin disorders. The potential areas of research and development that could lead to new applications in the fields of novel autoimmune diseases, precision medicine, neurological disorders, and combination therapies.


Full Text:

PDF

References


https://pubchem.ncbi.nlm.nih.gov/compound/Methotrexate

https://www.sciencedirect.com/topics/medicine-and-dentistry/methotrexate

https://acsjournals.onlinelibrary.wiley.com/doi/pdf/10.1002/1097-0142%28197801%2941%3A1%3C36%3A%3AAID-CNCR2820410108%3E3.0.CO%3B2-I

Koźmiński P, Halik PK, Chesori R, Gniazdowska E. Overview of Dual-Acting Drug Methotrexate in Different Neurological Diseases, Autoimmune Pathologies and Cancers. Int J Mol Sci. 2020 May 14;21(10):3483. doi: 10.3390/ijms21103483. PMID: 32423175; PMCID: PMC7279024.

Hanoodi M, Mittal M. Methotrexate. [Updated 2023 Aug 16]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK556114/

Sathasivam S. Steroids and immunosuppressant drugs in myasthenia gravis. Nat. Clin. Pract. Neurol. 2008;4:317–327. Doi: 10.1038/ncpneuro0810.

J. A. M. Wessels, T. W. J. Huizinga, H.-J. Guchelaar, Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis, Rheumatology, Volume 47, Issue 3, March 2008, Pages 249–255, https://doi.org/10.1093/rheumatology/kem279

McGeer P.L., Rogers J., McGeer E.G., Sibley J. Anti-inflammatory drugs and Alzheimer disease. Lancet. 1990;335:1037. Doi: 10.1016/0140-6736(90)91101-F

Zhou M., Xu R., Kaelber D.C., Gurney M.E. Tumor Necrosis Factor (TNF) blocking agents are associated with lower risk for Alzheimer’s disease in patients with rheumatoid arthritis and psoriasis. PLoS ONE. 2020;15:e0229819. Doi: 10.1371/journal.pone.0229819.

Shen S., O’Brien T., Yap L.M., Prince H.M., McCormack C.J. The use of methotrexate in dermatology: A review. Australas. J. Dermatol. 2012;53:1–18. Doi: 10.1111/j.1440-0960.2011.00839.x.


Refbacks

  • There are currently no refbacks.